Eli Lilly Obesity Drug - Search News

Wegovy, Zepbound and Eli Lilly

Barron's on MSN · 7h

Eli Lilly’s Weight-Loss Drug Zepbound More Effective than Novo’s Wegovy, Study Shows

Eli Lilly’s obesity drug Zepbound is more effective than rival Novo Nordisk’s drug Wegovy, a head-to-head trial showed, Lilly said in a statement Wednesday. On average, Zepbound led to a superior weight loss of 20.

Hosted on MSN · 4h

Eli Lilly’s Zepbound Beats Novo Nordisk’s Wegovy in First Head-to-Head Study

People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s drug.

USA Today · 5h

Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.

4h

Lilly's tirzepatide challenges semaglutide in obesity drug market

The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem ...

Race is on for oral obesity drugs with multiple phase 3 trials vying for next-gen status in a $126B market

Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results